초록 ▼

○ 연구결과
- 국내 천연물 추출물의 지방간 개선개발의 표적이 되는 생체분자를 이용하여 cell-based 스크리닝 기능성 개선 소재로의 활용 극대화
- 기능성 개선소재 개발의 대량생산 방법, 조성 파악 및 구조분석하여 소재 개발하였음
- 어성초를 이용한 기능성 개선 소재의 약리활성을 표적 단백질을 통해 최적화
- 모델동물로 부터 지방간을 위한 기능성 개선 소재의 효력 검증했음
- 어성초를 이용한 고부가가치 창출이 가능한 기능성 간 에방 및 치료개선 개선소재 개발하였음
- 지방간 개선소재를 함유한 시

○ 연구결과
- 국내 천연물 추출물의 지방간 개선개발의 표적이 되는 생체분자를 이용하여 cell-based 스크리닝 기능성 개선 소재로의 활용 극대화
- 기능성 개선소재 개발의 대량생산 방법, 조성 파악 및 구조분석하여 소재 개발하였음
- 어성초를 이용한 기능성 개선 소재의 약리활성을 표적 단백질을 통해 최적화
- 모델동물로 부터 지방간을 위한 기능성 개선 소재의 효력 검증했음
- 어성초를 이용한 고부가가치 창출이 가능한 기능성 간 에방 및 치료개선 개선소재 개발하였음
- 지방간 개선소재를 함유한 시제품 제작, 기시법 확보, 건기식 허가용 전임상 준비하였음.
- 대량 생산을 위한 기능성 개선 소재의 정량적 분리 및 정제의 최적화하였음
- 천연물 추출물 단독 혹은 복합 혼합하여 지방간에 선택․특이적인 기능성 개선소재 개발하여 밝혔음.

Abstract ▼

Active ingredients for liver function were identified from Houttuynia cordata. A process was developed for industrial production, and the product(extract) was applied to food products.
1) Extraction and identification of active ingredient
- A process using 70% ethanol was developed as an effic

Active ingredients for liver function were identified from Houttuynia cordata. A process was developed for industrial production, and the product(extract) was applied to food products.
1) Extraction and identification of active ingredient
- A process using 70% ethanol was developed as an efficient extraction method,
- The extract was fractionated depending on antioxidative activity.
- Active ingredients were purified from the fractions and their structure were identified by NMR, LC/MS, etc.
- As results, quercetin, quercitrin and caffeic acid were identified from as extract of Houttuynia cordata.
2) Anti-inflammatory Effects of Houttuynia cordata Extract
- Ethyl actetae (HC-EA) extract of H. cordata significantly scavenged DPPH free radicals in a concentration-dependent fashion. The increased levels of NO, iNOS and IL-6 in LPS-stimulated BV-2 microglial cells were also suppressed by HC-EA extract in a concentration-dependent manner.
- HC-EA extract exhibited strong anti-oxidant properties and inhibited the excessive production of pro-inflammatory mediators, including NO, iNOS and IL-6, in LPS stimulated BV-2 cells.
3) Hepatoprotective and Anti-hyperlipidemic Effect of Houttuynia cordataa gainst Carbon Tetrachloride-Induced Hepatic Damage In Experimental Mice
- CCl4-induced morphological changes in hepatocyte architecture were studied by haematoxylin and eosin (H&E) staining. In vitro alkyl and hydroxyl free radical scavenging assays were performed to evaluate the antioxidant effect of HCE.
- Administration of HCE extract significantly reduced the elevated serum levels of AL T, AST, and ALP and regulated the altered levels of total serum cholesterol, TG, HDL and LDNLDL levels in CCl4-induced hepatotoxicity in mice.
- The morphological changes in hepatocyte architecture were also reversed by HCE pre-treatment. Further, HCE showed significant antioxidant actions by scavenging the alkyl and hydroxy I free radicals.
HCE extract exhibited hepatoprotective and anti -hyperlipidemic activities in CCl4-inducedhepatotoxicityinmice
4) Houttuynia cordata extract attenuates the expression of lipogenic genes in human HepG2 hepatocytes via activation of AMPK and inhibition of lipid biosynthesis
- HepG2 cells were pretreated with various concentration of HCE (0, 10, 20, 40 and 80 g/mD and treated with serum-free medium with normal glucose (5 mM) for 1 h, followed by exposure to high glucose (25 mM D-glucose) for 24 h.
- HCE attenuated lipid accumulation in human HepG2 hepatocytes when exposed to high glucose (25 mM D-glucose) significantly and dose dependently (p<0.05, p<0.01 and p<0.001 at 20, 40 and 80 ug/ml concentrations), respectively.
- HCE attenuated the expression of fatty acid synthase (FAS) and sterol regulatory element-binding protein-1 (SREBP-l). The adenosine monophosphate-activated protein kinase (AMPK) was also activated by HCE treatment when exposed to high glucose (25 mM D-glucose) in human HepG2 hepatocytes.
5) Houttuynia cordata Thunb (Saururaceae) alleviates high-fat diet-induced non-alcoholic fatty liver in experimental rats
- Investigated the effects of H. cordata ethyl acetate (HC-EA) extract on high-fat diet (HFD)-induced hepatic steatosis and elucidated the molecular mechanisms involved in an animal model of non-alcoholic steatohepatitis (NASH). After being fed a HFD for two weeks, rats were orally dosed with HC-EA extract (100, 200, or 300 mg;kg) once daily for 6 weeks.
- HC-EA extract induced dose-dependent reductions in plasma lipid levels, decreased the overall hepatic lipid accumulation and improved HFD-induced hepatic histological lesions.
- The morphological changes observed using Hematoxylin-Eosin and Oil-Red 0 staining in HFD fed rat hepatocytes were reversed with HC-EA treatment.
- Mechanistic study revealed that HC-EA extract enhanced the phosphorylation of AMP-activated protein kinase (AMPK) and its primary downstream targeting enzyme, acetyl-CoA carboxylase, up-regulated the gene expression of carnitine palmitoyl transferase
1, and down-regulated sterol regulatory element binding protein 1, fatty acid synthase, and glutamate pyruvate transaminase protein levels in the livers of HFD-fed rats.
- HC-EA extract might act by regulating the AMPK-dependent signaling pathway and related mediators.
6) Development of manufacturing process and Application of extract to food products
- An efficient process using absorptive resin was developed for preparation of food material.
- Basic characterization of the extact, such as composition, heat stability and taste, were performed.
- The extract was applied to 4 type of food (liquid pouch, stick, tablet and capsule), and changes according to time were investigated.
- Standard operation procedure and basic specification including test methods were prepared for production.
In summary, HC-EA extract might be developed as a pronusmg strategy for the prevention and treatment of obesity-related non-alcoholic disease.

목차 Contents

• 표지 ... 1
• 제출문 ... 2
• 요약문 ... 3
• SUMMARY(영문요약문) ... 9
• CONTENTS(영문목차) ... 12
• 목차 ... 13
• 제1장 연구개발과제의 개요 ... 14
• 제1절 연구개발 목표 ... 14
• 제2절 연구개발 필요성 ... 14
• 제3절 연구개발 범위 ... 22
• 제4절 연구개발 추진체계 ... 23
• 제5절 연구개발의 기대효과 ... 24
• 제2장 국내외 기술개발 현황 ... 26
• 제3장 연구개발수행 내용 및 결과 ... 33
• 가. 국내산 어성초 추출물의 추출 및 정제 ... 33
• 나. 어성초 추출물의 성분분석 ... 39
• 다. 어성초 추출물의 효능 및 안전성 ... 51
• 라. 어성초 추출물의 제조공정 개발 ... 109
• 마. 어성초 추출물의 생산시료의 특성 ... 111
• 바. 적용성 시험 ... 112
• 제4장 목표달성도 및 관련분야에의 기여도 ... 129
• 목표달성도 ... 129
• 관련분야 기여도 ... 130
• 제5장 연구개발 성과 및 성과활용 계획 ... 131
• 가. 연구개발결과의 성과 및 활용목표 대비 실적 ... 131
• 나. 눈문게재 성과 ... 131
• 다. 특허 성과 ... 133
• 라. 기술료 징수 현황 ... 135
• 마. 사업화 현황 ... 135
• 바. 인력활용/양성 성과 ... 135
• 사. 경제사회 파급효과 ... 137
• 제6장 연구개발과정에서 수집한 해외과학기술정보 ... 137
• 제7장 연구시설·장비 현황 ... 139
• 제8장 참고문헌 ... 139
• 끝페이지 ... 142